AI Stock Analysis - Vaxart (VXRT)
Analysis generated August 28, 2025.
Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant vaccines based on its proprietary VAAST platform. It aims to revolutionize the approach to immunizations by providing oral vaccines that drive both systemic and mucosal immune responses, potentially offering a higher degree of protection and convenience compared to traditional injectable vaccines.
Stock Alerts - Vaxart (VXRT)
 |
Vaxart | February 13 Price is down by -6.2% in the last 24h. |
|
Vaxart | February 5 Price is down by -6% in the last 24h. |
|
Vaxart | January 30 Price is down by -11.5% in the last 24h. |
|
Vaxart | January 16 Price is up by 11% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Vaxart
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 99 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 406 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 74,737 | Sign up | Sign up | Sign up |
| X Mentions | 8 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Vaxart
Vaxart, Inc., a clinical-stage biotechnology company, is dedicated to the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company is headquartered in South San Francisco, California.
| Price | $0.57 |
| Target Price | Sign up |
| Volume | 228,510 |
| Market Cap | $136M |
| Year Range | $0.3 - $0.8 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS InsiderFebruary 5 - GlobeNewswire |
|
 |
Another Approval and More NextGen Covid Vax News (Update No 37)January 30 - Plos.org |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 72M | 0 | 72M | -8.1M | -5.4M | -0.040 |
| Q2 '25 | 40M | 0 | 40M | -15M | -12M | -0.070 |
| Q1 '25 | 21M | 0 | 21M | -16M | -12M | -0.070 |
| Q4 '24 | 15M | 1.1M | 15M | -12M | -8.6M | -0.050 |
| Q3 '24 | 4.9M | 0 | 4.9M | -14M | -11M | -0.060 |
Insider Transactions View All
| Watson W. Mark filed to buy 124,125 shares at $0.4. December 5 '25 |
| HERON ELAINE J filed to buy 96,566 shares at $0.4. November 21 '25 |
| HERON ELAINE J filed to buy 79,783 shares at $0.4. November 21 '25 |
| Watson W. Mark filed to buy 119,125 shares at $0.4. December 5 '25 |
| Finney Kevin filed to buy 204,771 shares at $0.4. August 19 '25 |
Similar companies
Read more about Vaxart (VXRT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions & customer reviews.
FAQ - Vaxart
The Market Cap of Vaxart is $136M.
Currently, the price of one share of Vaxart stock is $0.57.
The VXRT stock price chart above provides a comprehensive visual representation of Vaxart's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Vaxart shares. Our platform offers an up-to-date VXRT stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Vaxart (VXRT) does not offer dividends to its shareholders. Investors interested in Vaxart should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Vaxart are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
